Trial Profile
A 12-MONTH OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS 1 MONTH TO 16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES AND PEDIATRIC AND ADULT SUBJECTS 5 TO 65 YEARS OF AGE WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary)
- Indications Partial epilepsies; Tonic-clonic epilepsy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Pfizer
- 17 Sep 2019 Status changed from active, no longer recruiting to completed.
- 19 Jul 2019 Planned End Date changed from 1 Aug 2019 to 15 Aug 2019.
- 19 Jul 2019 Planned primary completion date changed from 1 Aug 2019 to 15 Aug 2019.